UpMarketResearch offers a latest published report on Global Anti-Osteoporosis Therapy And Fracture Healing Market industry analysis and forecast 20192025 delivering key insights and providing a competitive advantage to clients through a detailed report. This is a latest report, covering the current COVID-19 impact on the market Continue reading →

There used to be a running joke in my family. Continue reading →

At first glance, you see a profile of a professional mountain bike racer. Highly focused, physically and mentally tough, has a to-the-point bluntness about it all. UCI World Cup competitor Kate Weatherly is 100 percent that racer. Continue reading →

Its Pride Month, but a very different one to those seen in previous years. Continue reading →

The inherent, ineluctable unpredictability of biology can be the basis for biological patent claims being non-obvious (lacking the requisite "reasonable expectation of success"; see, e.g., OSI Pharmaceuticals v. Apotex) and for the greater quantum of disclosure necessary to satisfy the written description and enablement requirements of 112 (see, e.g., Amgen v Continue reading →

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-361 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of overall survival (OS) or progression-free survival (PFS), compared with standard of care chemotherapy. In the final analysis of the study, there was an improvement in OS and PFS for patients treated with KEYTRUDA in combination with chemotherapy (cisplatin or carboplatin plus gemcitabine) compared to chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan Continue reading →